| Literature DB >> 26629904 |
Xiang Li1, Chenxia Li1, Rong Wang1, Juan Ren2, Jian Yang1, Yuelang Zhang1.
Abstract
OBJECTIVE: Gadoxetic acid disodium (Gd-EOB-DTPA) is a magnetic resonance imaging (MRI) contrast agent to target the liver cells with normal function. In clinical practice, the Gd-EOB-DTPA produces high quality hepatocyte specific image 20 minutes after intravenous injection, so DWI sequence is often performed after the conventional dynamic scanning. However, there are still some disputes about whether DWI sequence will provide more effective diagnostic information in clinical practice. This study aimed to explore the diagnostic value of combining Gd-EOB-DTPA-enhanced MRI and DWI in the detection of hepatocellular carcinoma (HCC) in patients with chronic liver disease.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26629904 PMCID: PMC4668097 DOI: 10.1371/journal.pone.0144247
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of study selection.
Basic characteristics of included literatures.
| Author | Year | Cases | Lesion | M/F | Age(Scope) | Size(Scope) | Gold standard | Study design | Basic disease | Diagnosis | Equipment |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 2010 | 59 | 113 | 50/9 | 57 (29–75) | 2.8 (0.4–11) | P | R | C | 1 | 1.5T+3.0T |
|
| 2012 | 51 | 73 | 43/8 | ND | 2.98(0.2–10) | P/I | R | C/H | 1 | 3.0T |
|
| 2013 | 100 | 125 | 57/43 | 57.9(29–91) | ND | P/I | R | C | 1 | 1.5T+3.0T |
|
| 2010 | 58 | 109 | 39/19 | 63(35–84) | 1.8(0.3–7.0) | P/I | P | C | 1 | 1.5T |
|
| 2011 | 52 | 60 | 60/15 | 54.7 (42–67) | 1.74 (0.5–2.8) | P/I | R | C | 1 | 1.5T |
|
| 2009 | 62 | 83 | 54/8 | 55(31–76) | 2.9 (0.5–10.5) | P | P | C/H | 1 | 3.0T |
|
| 2012 | 34 | 60 | 30/4 | 57(30–66) | 1.44 (0.4–3.0) | P | R | C/H | 1 | 3.0T |
|
| 2010 | 69 | 97 | 56/13 | ND | 1.37 ± 0.41 | P/I | R | C | 1 | 3.0T |
|
| 2014 | 63 | 160 | 54|9 | 52(33–68) | 2(0.5–7.8) | P | R | C/H | 2 | 3.0T |
|
| 2011 | 40 | 42 | UN | UN | UN | P | R | C | 2 | 3.0T |
|
| 2013 | 54 | 87 | 40/14 | 68.8±10.5 | 1.84(0.3–6.5) | P | R | C | 2 | 1.5T |
|
| 2012 | 260 | 323 | 185/75 | 55.1±7.9 | • ≤2.0 | P | R | L | 2 | 3.0T |
|
| 2015 | 43 | 53 | 34/9 | 66(46–82) | 2.17(1–4) | P | R | C | 2 | 1.5T |
aND, not documented.
bUN, unclear.
cP, Pathological follow up.
dI, Imaging follow up.
eR, Retrospective study.
fP, Prospective study.
gC, Cirrhosis.
hH, Hepatitis.
iL, Chronic liver disease.
j1, Gd-EOB-DTPA-enhanced MRI
k2, Gd-EOB-DTPA-enhanced MRI and DWI
Various indicators of included literatures.
| Author | Year | TP | FP | FN | TN | Se | Sp |
|---|---|---|---|---|---|---|---|
|
| 2010 | 77 | 2 | 7 | 27 | 91.7 | 93.1 |
|
| 2012 | 67 | 4 | 6 | 33 | 91.8 | 89.2 |
|
| 2013 | 63 | 14 | 7 | 42 | 90.9 | 74.2 |
|
| 2010 | 74 | 2 | 13 | 20 | 85 | 91 |
|
| 2011 | 52 | 4 | 8 | 35 | 86.7 | 89.7 |
|
| 2009 | 78 | 1 | 5 | 48 | 94 | 97.96 |
|
| 2012 | 27 | 5 | 2 | 26 | 93.1 | 83.9 |
|
| 2010 | 41 | 2 | 3 | 51 | 96.2 | 93.2 |
|
| 2014 | 89 | 3 | 24 | 44 | 78.8 | 91.5 |
|
| 2011 | 21 | 2 | 10 | 8 | 68 | 73 |
|
| 2013 | 83 | 15 | 4 | 339 | 95.4 | 95.7 |
|
| 2012 | 165 | 4 | 14 | 140 | 92.4 | 97.5 |
|
| 2015 | 41 | 0 | 1 | 11 | 97.6 | 100 |
aTP, true positive value.
bFP, false positive value.
cFN, false negative value.
dTN, true negative value.
eSe, sensitivity.
fSp, specificity.
Evaluation on included and excluded literatures.
| Author | Case representation | Clear inclusion criteria | Gold standard reliability | Time between gold standard and test | Sample accepts criteria | Same gold standard | Gold standard independence | Clear test description | Clear gold standard description | Blinded test | Blinded gold standard | Obtained same clinical data | Difficult interpretation of results | Exit explanation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
|
| Y | Y | Y | Un | Y | N | Y | Y | Y | Y | Un | Y | Y | Y |
|
| Y | Y | Y | Un | Y | N | Y | Y | Y | Y | Un | Y | Y | Y |
|
| Y | Y | Y | Y | Y | N | Y | Y | Y | Un | Un | Y | Y | Y |
|
| Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y |
|
| Y | Y | Y | Un | Y | Y | Y | Y | Y | Y | Un | Y | Y | Y |
|
| Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N |
|
| Y | Y | Y | Un | Y | Y | Y | Y | Y | Y | Un | Y | Y | Y |
|
| Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Un | Y | Y | Y |
|
| Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Un | Un | Y | N |
|
| Y | Y | Y | Un | Y | Y | Y | Y | Y | Y | Un | Y | Y | Y |
|
| Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Un | Y | Y | N |
|
| Y | Y | Y | Un | Y | N | Y | Y | Y | Y | Un | Y | Y | Y |
|
| Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Un | Y | Y | Y |
|
| ||||||||||||||
|
| Y | Un | Y | Y | Y | Y | Y | Y | N | Y | Un | Un | Y | N |
|
| Y | Y | Y | Un | Y | N | Un | Y | N | Y | Un | Y | Y | Y |
|
| N | Y | Y | Y | Y | Y | Y | Y | N | Un | Un | N | Y | Y |
aThe quality of literature was evaluated using the quality assessment of diagnostic accuracy studies (QUADAS) [20]
bliterature excluded by more than 4 in "no" or "Unclear" answer in QUADAS
Y, Yes; Un, Unclear; N, No.
Fig 2Heterogeneity test results.
(A) the estimates for Gd-EOB-DTPA-enhanced MRI in HCC diagnosis. (B) the estimates for combination of Gd-EOB-DTPA-enhanced MRI and DWI sequence in HCC diagnosis.
Fig 3Funnel plot of the estimates for Gd-EOB-DTPA-enhanced MRI in HCC diagnosis.
(A) sensitivity analysis. (B) specificity analysis. (C) positive likelihood ratio analysis. (D) negative likelihood ratio analysis.
Fig 4Forest plots of the estimates for Gd-EOB-DTPA-enhanced MRI in HCC diagnosis.
(A) sensitivity analysis. (B) specificity analysis. (C) positive likelihood ratio analysis. (D) negative likelihood ratio analysis.
Fig 5Forest plots of the estimates for combination of Gd-EOB-DTPA-enhanced MRI and DWI sequence in HCC diagnosis.
Fig 6Summary receiver operating characteristic curves (SROC).
(A) SROC curve for Gd-EOB-DTPA-enhanced MRI in HCC diagnosis. (B) SROC curve for combination of Gd-EOB-DTPA-enhanced MRI and DWI sequence in HCC diagnosis.
Meta regression analysis.
| Variable | Coefficient | Standard error | P value | RDOR | [95%CI] |
|---|---|---|---|---|---|
|
| 32.418 | 14.3682 | 0.2656 | — | — |
|
| -0.495 | 0.2772 | 0.3252 | 0.61 | (0.02;20.65) |
|
| -0.049 | 0.0358 | 0.4009 | 0.95 | (0.60;1.50) |
|
| 0.041 | 0.0505 | 0.5692 | 1.04 | (0.55;1.98) |
|
| 1.436 | 1.2792 | 0.4633 | 4.20 | (0.00;48126481.50) |
|
| -0.742 | 1.2436 | 0.6575 | 0.48 | (0.00;3470717.50) |
|
| -2.000 | 0.8555 | 0.8535 | 0.82 | (0.00;43030.13) |
aBaek CK [24] The average age was not recorded, and was replaced by the mean of the age range.
bTwo categorical variable analysis was performed according to the diameter of liver cell carcinoma >3cm or ≤3cm.
RDOR, relative diagnostic odds ratios.